Revista Brasileira de Hematologia e Hemoterapia Revista Brasileira de Hematologia e Hemoterapia
Rev Bras Hematol Hemoter 2017;39:93-4 DOI: 10.1016/j.bjhh.2017.01.002
Erratum
Erratum to “Diagnosis and treatment of chronic lymphocytic leukemia: Recommendations from the Brazilian Group of Chronic Lymphocytic Leukemia” [Rev Bras Hematol Hemoter. 2016;38(4):346–357]
Celso Arrais Rodriguesa,b,, , Matheus Vescovi Gon??alvesa,c, Maura Rosane Val??rio Ikomad, Irene Lorand-Metzee, Andr?? Domingues Pereirab, Danielle Le??o Cordeiro de Fariasf, Maria de Lourdes Lopes Ferrari Chauffaillea,c, Rony Schaffelg, Eduardo Fl??vio Oliveira Ribeiroh, Talita Silveira da Rochai,j, Valeria Buccherik, Yuri Vasconcelosl, Vera L??cia de Piratininga Figueiredom, Carlos S??rgio Chiattonej,n, Mihoko Yamamotoa, on behalf of the Brazilian Group of Chronic Lymphocytic Leukemia
a Universidade Federal de S??o Paulo (UNIFESP), S??o Paulo, SP, Brazil
b Hospital S??rio Liban??s, S??o Paulo, SP, Brazil
c Fleury Medicina e Sa??de, S??o Paulo, SP, Brazil
d Hospital Amaral Carvalho, Ja??, SP, Brazil
e Universidade Estadual de Campinas (UNICAMP), S??o Paulo, SP, Brazil
f Universidade Federal de Goi??s (UFG), Goi??nia, GO, Brazil
g Universidade Federal do Rio de Janeiro (UFRJ), Rio de Janeiro, RJ, Brazil
h Hospital Santa L??cia, Bras??lia, DF, Brazil
i A.C Camargo Cancer Center, S??o Paulo, SP, Brazil
j Santa Casa de Miseric??rdia de S??o Paulo, S??o Paulo, SP, Brazil
k Instituto do C??ncer do Estado de S??o Paulo (ICESP), S??o Paulo, SP, Brazil
l Instituto Goiano de Oncologia e Hematologia (INGOH), Goi??nia, GO, Brazil
m Instituto de Assist??ncia M??dica ao Servidor P??blico Estadual (IAMSPE), S??o Paulo, SP, Brazil
n Hospital Samaritano, S??o Paulo, SP, Brazil

In the article “Diagnosis and treatment of chronic lymphocytic leukemia: recommendations from the Brazilian Group of Chronic Lymphocytic Leukemia”, published in Rev Bras Hematol Hemoter 2016;38:346–57, please consider the following correction:

2) Relapsed first-line treatment:

  • a)

    Progress after 24 months: repeat first-line treatment (add an anti-CD20 antibody if not used in the first-line treatment)

  • b)

    Progress within 24 months:

    • -

      ‘Go-go’ patients: ibrutinib

      • Alternative options: venetoclax, alemtuzumab with or without methylprednisolone, rituximab with or without high-dose methylprednisolone, allogeneic HCST, bendamustine plus rituximab

    • -

      ‘Slow-go’ patients: ibrutinib

      • Alternative options: idelalisib plus rituximab, alemtuzumab with or without methylprednisolone, rituximab with or without high-dose methylprednisolone bendamustine plus rituximab, FCR-lite

Copyright © 2016. Associação Brasileira de Hematologia, Hemoterapia e Terapia Celular
Rev Bras Hematol Hemoter 2017;39:93-4 DOI: 10.1016/j.bjhh.2017.01.002